vitaxin vitaxin vitaxin (medi-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3. it is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. vitaxin was in 2002 being studied for rheumatoid arthritis. it is the developmental precursor of etaracizumab (medi-522). both are derived from the mouse antibody lm609. vitaxinmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetalpha-v beta-3 integrinclinical datatrade namesvitaxinatc codenoneidentifierschemspidernone ny (what is this?) vitaxin is safe for humans. it has little effect on advanced cancer.